Betamethasone Acetate Market, by Formulation (Suspension, Ointment, and Gel), by Route of Administration (Intramuscular, Intra-articular, and Intradermal), by Application (Respiratory Disease, Renal Disease, Gastrointestinal Disease, Ophthalmic Disease, Dermatological Disease, and Others), by Age Group (Pediatric and Geriatric), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Betamethasone acetate is an acetate ester, a steroid ester, a 17alpha-hydroxy steroid, a 20-oxo steroid, a fluorinated steroid, an 11beta-hydroxy steroid, a 3-oxo-Delta (1), Delta (4)-steroid and a tertiary alpha-hydroxyl ketone. It is functionally related to a betamethasone.
Betamethasone acetate is long-acting corticosteroid has anti-inflammatory and immunosuppressive effects. It can be administered parenterally to treat a number of disease states, including autoimmune illnesses, and topically to treat inflammatory skin conditions including eczema. Betamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). Betamethasone injectable suspension is used to treat inflammation and pain from a variety of conditions. These conditions include multiple sclerosis, arthritis, and others.
Market Dynamics
The betamethasone acetate is used in various disease conditions such as renal disease, thus the increasing prevalence of renal disease is expected to drive the market growth over the forecast period. For instance, in July 2022, according to data provided by Center of Disease Control and Prevention (CDC), in 2020, more than 15% of the U.S. adults or 37 million people, are estimated to have Chronic Kidney Disease (CKD). Moreover, according to same source CKD is more common in people aged 65 years or older (38%) than in people aged 45–64 years (12%) or 18–44 years (6%).
The betamethasone acetate is used in various disease condition such as respiratory diseases, thus the increasing prevalence of respiratory disease is expected to drive the betamethasone acetate market growth over the forecast period. For instance, in August 2021, according to the World Health Organization (WHO), in 2020 approximately, 65 million people had moderate to severe Chronic Obstructive Pulmonary Diseases (COPD) that accounts for 5% of deaths (41.9 deaths per 100 000 individuals) globally.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook